Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

← catalyst calendar

NCT04710576 · results posted

Sponsored by Syndax Pharmaceuticals (industry) · SNDX — their whole pipeline →.

Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
296estimated
Sites
121
Countries
Australia, Belgium, Canada +13

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2021-03-04actualWhen the study began enrolling
Primary completion2023-04-07actualThe date the last participant is measured for the primary outcome — the readout window
Study completionSep 2027estimatedThe whole study's end, after follow-up
First posted2021-01-14actualWhen this record first appeared on the registry
Results posted2024-10-10actualWhen the sponsor posted results to the registry
Record updated2026-06-16actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Chronic Graft-versus-host-disease

Intervention

  • Drug: Axatilimab — also filed as Niktimvo, SNDX-6352

Primary outcome

what the primary-completion date above is the date OF
Overall Response Rate (ORR) in the First 6 Cycles as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease (cGVHD)
measured First 6 cycles (up to Cycle 7 Day 1; each cycle = 4 weeks)

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2023-04-05 · 1.7 MB · Prot_000.pdf
Statistical Analysis Planposted 2023-06-27 · 516 KB · SAP_001.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · SNDX's whole pipeline · Catalyst calendar · Every registered study · What changed